TD Cowen raised the firm’s price target on Gilead (GILD) to $100 from $95 and keeps a Buy rating on the shares. The firm said they posted a ...

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Overweight rating on the ...

According to preliminary data, the S&P 500 lost 16.58 points, or 0.28%, to end at 6,051.92 points, while the Nasdaq Composite ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

Salesforce has announced a new CFO+ with an expanded set of responsibilities as a company veteran who "bleeds CRM" prepares ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

Gilead KOA Holiday has been recognized with the prestigious KOA ICON Award. This recognition highlights campgrounds that demonstrate exceptional operational excellence, customer satisfaction, and a ...

Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing. Gilead had reached an inflection point ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...